Teva Pharma (TEVA) Guides FY09, FY10 Inline With the Street
More News related to TEVA
- Protalix BioTherapeutics (PLX) Sees Interest On Renewed Takeover Talk
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
More News related to Guidance
- Top 10 News Items 11/23-11/27: Dubai Debt Fallout; Gold; GDP Revised Lower; Diedrich Coffee Bidding War
- Trading Radar for 11/30: Inergy Holdings (NRGP), Golar (GLNG), Omnivision (OVTI), Knightsbridge (VLCCF) Report
- Notable Mergers and Acquisitions of the Day for 11/27: F, S/IPCS, STAR/CSCO, HRAY
- Notable Analyst Rating Changes 11/27: TIF, QLTI Upgraded; FSNM, RGFC Downgraded
- Notable ETF Movers *Special Dubai World Edition* 11/27: UUP Higher; GAF, EEM, FXI, XLF Lower
Teva Pharma (Nasdaq: TEVA) sees FY09 EPS of $3.30-$3.40, versus the consensus of $3.36, and FY10 EPS of $4.40-$4.60, versus the Street estimate of $4.48.
Related Categories
GuidanceStocks Mentioned
-0.28Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
